Literature DB >> 11412040

An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway.

M A Olayioye1, A Badache, J M Daly, N E Hynes.   

Abstract

ErbB receptor tyrosine kinases are activated by multiple ligands such as epidermal growth factor (EGF) and neuregulins (NRGs), leading to stimulation of intracellular signaling pathways, including the mitogen-activated protein kinase (MAPK) cascade. We show here that Src kinase is essential for rapid EGF- and NRG-induced MAPK activation when the breast carcinoma cell lines T47D and SKBR3 are stimulated with low concentrations of ligand. In the presence of the pharmacological inhibitor CGP77675, which specifically blocks the activity of Src family kinases, ligand-induced MAPK activation was almost completely blocked at 5 min. Although this block was only transient, inactivation of Src suppressed ligand-induced transcription from a MAPK-responsive promoter. At the molecular level, the initial inhibition of MAPK by Src inactivation correlated with impaired ligand-induced Shc phosphorylation. Surprisingly, Src inhibition affected neither association of Shc with ErbB receptors nor phosphorylation of receptor-bound Shc. Thus, ErbB signaling requires the engagement of a novel Src-dependent route to MAPK, to trigger its rapid activation and subsequent efficient stimulation of transcription. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11412040     DOI: 10.1006/excr.2001.5242

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  17 in total

1.  Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.

Authors:  Siyuan Zhang; Wen-Chien Huang; Ping Li; Hua Guo; Say-Bee Poh; Samuel W Brady; Yan Xiong; Ling-Ming Tseng; Shau-Hsuan Li; Zhaoxi Ding; Aysegul A Sahin; Francisco J Esteva; Gabriel N Hortobagyi; Dihua Yu
Journal:  Nat Med       Date:  2011-03-13       Impact factor: 53.440

2.  Dasatinib suppresses invasion and induces apoptosis in nasopharyngeal carcinoma.

Authors:  Yu-Jie Li; Yi-Fu He; Xing-Hua Han; Bing Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

3.  Genetic deletion of endothelial microRNA-15a/16-1 promotes cerebral angiogenesis and neurological recovery in ischemic stroke through Src signaling pathway.

Authors:  Ping Sun; Feifei Ma; Yang Xu; Chao Zhou; R Anne Stetler; Ke-Jie Yin
Journal:  J Cereb Blood Flow Metab       Date:  2021-04-28       Impact factor: 6.200

4.  Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.

Authors:  T Smirnova; Z N Zhou; R J Flinn; J Wyckoff; P J Boimel; M Pozzuto; S J Coniglio; J M Backer; A R Bresnick; J S Condeelis; N E Hynes; J E Segall
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

5.  Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway.

Authors:  Margarita Calvo; Ning Zhu; John Grist; Zhenzhong Ma; Jeffrey A Loeb; David L H Bennett
Journal:  Glia       Date:  2011-01-06       Impact factor: 7.452

Review 6.  Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members.

Authors:  M A Olayioye
Journal:  Breast Cancer Res       Date:  2001-10-04       Impact factor: 6.466

7.  Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.

Authors:  Q Chang; C Jorgensen; T Pawson; D W Hedley
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

8.  Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.

Authors:  Thomas Schlange; Yutaka Matsuda; Susanne Lienhard; Alexandre Huber; Nancy E Hynes
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

9.  Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3.

Authors:  Christian D Young; Erica C Nolte; Andrew Lewis; Natalie J Serkova; Steven M Anderson
Journal:  Breast Cancer Res       Date:  2008-08-13       Impact factor: 6.466

10.  Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.

Authors:  G Peiró; F Ortiz-Martínez; A Gallardo; A Pérez-Balaguer; J Sánchez-Payá; J J Ponce; A Tibau; L López-Vilaro; D Escuin; E Adrover; A Barnadas; E Lerma
Journal:  Br J Cancer       Date:  2014-06-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.